The short answer
High-dose niacin used to change cholesterol levels can increase muscle-toxicity risk with simvastatin. The concern is chiefly lipid-modifying nicotinic acid, generally at least 1 gram daily, rather than an automatic warning against every nutritional vitamin B3 dose.
What this answer covers
Oral simvastatin with niacin-containing products. Nicotinic acid, niacinamide and nutritional amounts require distinct interpretation.
- Supplement or preparation
- niacin
- Medication ingredient
- simvastatin
Which niacin products matter?
Check both the chemical form and total daily amount. Vitamin B3 products can contain nicotinic acid, nicotinamide or other derivatives, and high-strength bottles may deliver drug-like doses. They are not interchangeable for either cholesterol effects or adverse effects.
What does the evidence show?
A large trial added extended-release niacin with laropiprant to simvastatin-based treatment. Definite muscle injury was more frequent in the added-treatment group. The result concerns that pharmacologic combination, with population differences, and should not be turned into a risk estimate for an ordinary multivitamin.
What does current prescribing advice say?
ZOCOR advises against lipid-modifying niacin co-use in Chinese patients. For other patients, the prescriber should weigh benefit against muscle risk and monitor if combined treatment is chosen. This is a dose- and population-qualified instruction, not a blanket statement that all B3 is unsafe.
Does this mean I need more B3 or a timing gap?
No increased nutritional requirement or protective separation interval is established by these findings. Bring the bottle and reason for use to your pharmacist. Report unexplained muscle symptoms promptly, and let the prescriber decide whether either treatment should change.
Evidence and practical considerations
Side effects & toxicity
High-dose niacin used to change cholesterol levels can increase muscle-toxicity risk with simvastatin. The concern is chiefly lipid-modifying nicotinic acid, generally at least 1 gram daily, rather than an automatic warning against every nutritional vitamin B3 dose.
- Exact scope
- Oral simvastatin with niacin-containing products. Nicotinic acid, niacinamide and nutritional amounts require distinct interpretation. with Exact RxNorm 36567, IN, simvastatin; ZOCOR oral tablets. No substitution of lovastatin, pravastatin or another statin.
- Medication form and route
- oral
What remains uncertain
- Evidence concerns pharmacologic nicotinic acid. No proven depletion, extra B3 requirement or protective spacing interval. Trial formulation and population limits apply.
Factors that may matter: Exact preparation, dose, other medicines and baseline clinical condition matter..
Read the supporting source summaries
Source 1: regulatory prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: People prescribed oral simvastatin.
Advises avoiding grapefruit juice and describes dose- and population-qualified niacin muscle precautions.
How this applies: Restricted to the exact identities and conditions described in this article.
Does not establish a numerical risk for every juice, nutritional niacin dose or red yeast rice preparation.
Source 2: government nutrient reference
ods.od.nih.gov · Source check Sep 10, 2026
Population: People consuming nutritional or pharmacologic forms of vitamin B3.
Lipid-modifying nicotinic acid and nutritional B3 exposure are not interchangeable. Some supplements contain high doses.
How this applies: Restricted to the exact identities and conditions described in this article.
General nutrient guidance does not quantify a statin-specific interaction risk for every form.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 25,673 high-risk patients who passed a tolerability run-in.
Definite myopathy occurred in 75 versus 17 participants; risk ratio 4.4. Follow-up median 3.9 years.
How this applies: Restricted to the exact identities and conditions described in this article.
Combination niacin/laropiprant, not isolated nutritional B3. Run-in selection and population differences limit transfer; no atorvastatin-specific risk ratio.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Original-source assessment and consumer article prepared; exact claim dispositions, neutral findings and preparation limits recorded. | |
| Clinical sign-off is pending and no publication approval is asserted. | |
| Research summary published |
Article revision: e5ebb9c078b125cb
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.